AbbVie is projected to report Q3 2026 revenue of $17.35 billion and adjusted EPS of $3.74, with the stock currently trading at $286.99 against a median analyst target of $294.00. Investors are primarily focused on the growth of the immunology franchise, specifically whether Skyrizi and Rinvoq can continue to successfully offset the rapid revenue erosion of legacy drug Humira.
Management recently raised full-year guidance for Skyrizi, which analysts expect to generate $5.71 billion this quarter as it gains market share in inflammatory bowel disease. However, market sentiment is tempered by recent downward revisions to EPS estimates following a $216 million charge for acquired in-process research and development.